Johnson & Johnson (JNJ) was Reiterated by RBC Capital Mkts to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 133 from a previous price target of $125 . RBC Capital Mkts advised their investors in a research report released on Jul 20, 2016.
Many Wall Street Analysts have commented on Johnson & Johnson. Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.
On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.
Johnson & Johnson opened for trading at $123 and hit $123.22 on the upside on Monday, eventually ending the session at $123.14, with a gain of 0.11% or 0.14 points. The heightened volatility saw the trading volume jump to 65,99,199 shares. Company has a market cap of $338,714 M.
In a different news, on Jun 9, 2016, Gary J Pruden (Exec VP, WW Chair, Med Devices) sold 9,735 shares at $116.03 per share price. According to the SEC, on Jun 9, 2016, Ronald A Kapusta (Controller, CAO) sold 3,000 shares at $115.79 per share price. On Feb 4, 2016, Peter Fasolo (VP, Global Human Resources) sold 151,385 shares at $104.11 per share price, according to the Form-4 filing with the securities and exchange commission.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.